Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
| ▸ | MLNR | O43193 | 1/20 | 0.70 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.70 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | MC4R | P32245 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521176 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL29420217 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL3592 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL12342733 | 1.00 | CACNA2D1 (0.76) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL3280673 | 0.99 | CACNA2D1 (0.74) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL3358201 | 0.99 | CACNA2D1 (0.74) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL1535363 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL3312526 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Phosphoric Acid SCHEMBL1535335 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A | |
| Oxalic Acid SCHEMBL2740 | 0.93 | CACNA2D1 (0.67) | CACNA2D1SLC6A2SLC6A4SLC6A3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132192-B1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LTD (IN) | 2013-04-24 | — | — | EP | claimed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | claimed |
| US-7709662-B2 | Method of manufacturing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine) | ZENTIVA K.S. (CZ) | 2010-05-04 | — | — | US | claimed |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2010-04-29 | — | — | US | claimed |
| US-7550605-B2 | Process for preparation of an anitdepressant compound | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2009-06-23 | — | — | US | claimed |
| US-20090143600-A1 | METHOD OF MANUFACTURING (S)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | ZENTIVA, A.S. (CZ) | 2009-06-04 | — | — | US | claimed |
| EP-1758879-B1 | METHOD OF MANUFACTURING (S)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | ZENTIVA AS (CZ) | 2007-12-12 | — | — | EP | claimed |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | SUN PHAMACEUUTICAL INDUSTRIES LTD. (IN) | 2007-08-16 | — | — | US | claimed |
| WO-2006027798-A2 | A PROCESS FOR PREPARATION OF AN ANTIDEPRESSANT COMPOUND | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| EP-2172464-B1 | A method for the preparation of the hydrochloride salt from the duloxetine base | ZENTIVA KS (CZ) | 2015-08-26 | — | — | EP | disclosed |
| EP-2132192-B1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LTD (IN) | 2013-04-24 | — | — | EP | disclosed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | disclosed |
| US-8269023-B2 | Process for preparation of duloxetine hydrochloride | LUPIN LTD. (IN) | 2012-09-18 | — | — | US | disclosed |
| US-20080293952-A1 | Method for the Preparation of (S)-N-Methyl-3-(1-Naphthyloxy)-3-(2-Thienyl)Propylamine Hydrochloride (Duloxetine) | ZENTIVA K.S. (CZ) | 2008-11-27 | — | — | US | disclosed |
| WO-2008107911-A2 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | LUPIN LIMITED (IN) | 2008-09-12 | — | — | WO | disclosed |
| EP-1758879-B1 | METHOD OF MANUFACTURING (S)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | ZENTIVA AS (CZ) | 2007-12-12 | — | — | EP | disclosed |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | SUN PHAMACEUUTICAL INDUSTRIES LTD. (IN) | 2007-08-16 | — | — | US | disclosed |
| US-20060270861-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-11-30 | — | — | US | disclosed |
| WO-2006027798-A2 | A PROCESS FOR PREPARATION OF AN ANTIDEPRESSANT COMPOUND | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143600-A1 | METHOD OF MANUFACTURING (S)-N-METHYL-3-(1-NAPHTHYLOXY)-3-(2-THIENYL)PROPYLAMINE HYDROCHLORIDE (DULOXETINE) | PNMT, HTR3A, SLC6A3 | CACNA2D1 1015/4885SLC6A2 16/4885SLC6A4 6/4885 |
| US-20060270861-A1 | Process for the preparation of optically active (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine | DNTT, ERH, PNMT | CACNA2D1 809/4885SLC6A2 1856/4885SLC6A4 907/4885 |
| US-20080293952-A1 | Method for the Preparation of (S)-N-Methyl-3-(1-Naphthyloxy)-3-(2-Thienyl)Propylamine Hydrochloride (Duloxetine) | SLC6A3, PNMT, SLC6A2 | CACNA2D1 131/4885SLC6A2 3/4885SLC6A4 4/4885 |
| US-20100105925-A1 | NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE | MAOA, SLC6A3, PNMT | CACNA2D1 741/4885SLC6A2 19/4885SLC6A4 16/4885 |
| US-20070191616-A1 | Process for preparation of an antidepressant compound | TPH1, TPH2, HTR4 | CACNA2D1 908/4885SLC6A2 13/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.